Nutra Pharma Corp. Reports Significant Revenue Decline and Increased Losses in Q2 2026

Nutra Pharma Corp. reported its financial results for the second quarter of 2026, revealing a significant decline in revenue and an increase in losses compared to the same period in the previous year. For the three months ended June 30, 2026, the company generated net sales of $34,463, a decrease of approximately 59% from $84,532 in the same quarter of 2025. The six-month figures also reflected a downturn, with sales dropping to $61,709 from $158,506 year-over-year. The gross profit for the second quarter was $32,625, down from $63,428 in the prior year, while the total operating expenses surged to $468,089, compared to $353,957 in the same quarter of 2025.

The company reported a net loss of $3,948,772 for the second quarter of 2026, a stark contrast to a net income of $369,577 in the same quarter of 2025. This loss contributed to an accumulated deficit of $82,686,976 as of June 30, 2026. The increase in operating expenses was attributed to higher payroll, professional fees, and consulting expenses, which collectively rose to $289,350 from $187,224 in the previous year. Additionally, Nutra Pharma's derivative liabilities increased significantly, reflecting changes in the fair value of convertible notes and derivatives, which resulted in a loss of $3,405,443 for the quarter.

Operationally, Nutra Pharma's customer base remains concentrated, with sales to Avini Health, a related party, accounting for approximately 41% of total revenues in the second quarter. The company continues to face challenges in generating sufficient cash flow to sustain operations, ending the quarter with no cash on hand, down from $12,181 at the end of the previous fiscal year. The total liabilities increased to $21,831,616, up from $17,447,907 at the end of 2025, primarily due to rising accrued expenses and convertible notes payable.

Looking ahead, Nutra Pharma's management expressed concerns regarding the company's ability to continue as a going concern, citing a working capital deficit of $21,233,689 and the need for additional financing to execute its operating plan. The company is currently exploring options for raising capital, including debt and equity funding, but faces limitations due to its stock being listed on the OTC Market Group’s Expert Market. The management indicated that without adequate funding or a significant increase in sales, the company may struggle to meet its obligations and implement its business plans effectively.

In summary, Nutra Pharma Corp. is navigating a challenging financial landscape, marked by declining revenues, increasing losses, and a pressing need for capital to sustain operations. The company's future performance will depend on its ability to secure financing and improve sales of its pain relief products, which have been the cornerstone of its business strategy.